American Airlines Now Sees Q3 Total Revenue Higher Than Prior Guidance - Quick Facts

American Airlines Group Inc. (AAL) said, during the third quarter, the company flew 68.6 billion total available seat miles, down 9.6% versus the third quarter of 2019, compared to its prior guidance of down 8% to 10%. The company expects third-quarter total revenue to be up approximately 13% versus the third quarter of 2019, which is higher than its prior guidance of up 10% to 12%. American Airlines expects to report a pre-tax margin excluding net special items of approximately 4.5% in the third quarter, higher than the previous guidance of 2% to 4%. The company expects to report an operating margin of approximately 7% in the quarter.

American Airlines expects pretax income excluding net special items of $606 million, for the third quarter. Total revenue is expected to be $13.46 billion.

The company expects to end the third quarter with approximately $14.3 billion in total available liquidity.

Shares of American Airlines Group are up 5% in pre-market trade on Tuesday.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT